Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Stanford University
The First Affiliated Hospital of Zhengzhou University
Radiation Therapy Oncology Group
Candel Therapeutics, Inc.
Duke University
Baylor College of Medicine
Duke University
Radiation Therapy Oncology Group
Huashan Hospital
Hoffmann-La Roche
Duke University
Dr. Negrin University Hospital
Memorial Sloan Kettering Cancer Center
Biotech Pharmaceutical Co., Ltd.
Activartis Biotech
University of California, San Francisco
Duke University
National Cancer Institute (NCI)
University Hospital Freiburg